Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 140M | 138M | 139M | 135M | 142M |
| Gross Profit | 110M | 109M | 82M | 75M | 70M |
| Operating Income | 20M | 19M | 22M | 8M | -12M |
| EBITDA | 25M | 24M | 27M | 5M | -17M |
| Net Income | 16M | 15M | 16M | 22M | -22M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$10.51
+1.94% today
1Y Change
-37.10%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Spok Holdings, Inc. (SPOK) is a Healthcare stock with a market cap of $220.00M and listed on NASDAQ. The stock last traded around $10.51 and down 37.1% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +1.5%, EPS growth of +4.1%, a dividend yield of 11.9%. What stands out right now is revenue +1.5%, EPS +4.1%, free cash flow -2.0% with operating margin 12.0% and ROIC 7.6%. The dividend matters to the case here, with a current yield around 11.9%. Valuation is more restrained than many high-expectation growth names at P/E 17.3 and price/sales 1.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SPOK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPOK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SPOK Max Drawdown
-45.04%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SPOK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$142.2M
+5.7% YoY
FY Net Income
-$22.2M
-201.5% YoY
Free Cash Flow
-$7.3M
-371.2% YoY
Revenue Growth
+1.5%
EPS Growth
+4.1%
Gross Margin
87.1%
Net Margin
9.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 140M | 138M | 139M | 135M | 142M |
| Gross Profit | 110M | 109M | 82M | 75M | 70M |
| Operating Income | 20M | 19M | 22M | 8M | -12M |
| EBITDA | 25M | 24M | 27M | 5M | -17M |
| Net Income | 16M | 15M | 16M | 22M | -22M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25M | 29M | 32M | 36M | 45M |
| Total Assets | 206M | 217M | 228M | 244M | 248M |
| Total Liabilities | 60M | 62M | 64M | 72M | 74M |
| Shareholder Equity | 146M | 155M | 164M | 172M | 174M |
| Total Debt | 7M | 9M | 11M | 16M | 17M |
| Net Debt | -18M | -20M | -21M | -20M | -27M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8M
+23.4% YoY
Capital Expenditures
15M
-303.5% YoY
Free Cash Flow
7M
-371.2% YoY
Key ratios
Gross Margin
87.1%
Operating Margin
12.0%
Net Margin
9.3%
ROE
8.6%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.